Pasireotide for the treatment of Cushing's disease

Bibliography

• Arnaldi G, Angeli A, Atkinson AB, Diagnosis and complications of Cushing's syndrome: a consensus statement. J Clin Endocrinol Metab 2003;19:5593-602
   Google Scholar
• Nieman LK, Biller BM, Findling JW, The diagnosis of Cushing's syndrome: an Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab 2008;93:1526-40
   PubMed Web of Science ®Google Scholar
• Arnaldi G, Mancini T, Polenta B, Boscaro M. Cardiovascular risk in Cushing's syndrome. Pituitary 2004;7(4):253-6
   PubMedGoogle Scholar
• Pivonello R, Faggiano A, Lombardi G, The metabolic syndrome and cardiovascular risk in Cushing's syndrome. Endocrinol Metab Clin North Am 2005;34:327-39
   PubMed Web of Science ®Google Scholar
• Biller BM, Grossman AB, Stewart PM, Treatment of adrenocorticotropin-dependent Cushing's syndrome: a consensus statement. J Clin Endocrinol Metab 2008;93:2454-62
   PubMed Web of Science ®Google Scholar
• Bochicchio D, Losa M, Buchfelder M. Factors influencing the immediate and late outcome of Cushing's disease treated by transsphenoidal surgery: a retrospective study by the European Cushing's Disease Survey Group. J Clin Endocrinol Metab 1995;80(11):3114-20
   PubMed Web of Science ®Google Scholar
• Patil CG, Prevedello DM, Lad SP, Late recurrences of Cushing's disease after initial successful transsphenoidal surgery. J Clin Endocrinol Metab 2008;93:358-62
   PubMed Web of Science ®Google Scholar
• Prevedello DM, Pouratian N, Sherman J, Management of Cushing's disease: outcome in patients with microadenoma detected on pituitary magnetic resonance imaging. J Neurosurg 2008;109:751-9
   PubMed Web of Science ®Google Scholar
• Hammer GD, Tyrrell JB, Lamborn KR, Transsphenoidal microsurgery for Cushing's disease: initial outcome and long-term results. J Clin Endocrinol Metab 2004;89:6348-57
   PubMed Web of Science ®Google Scholar
• Atkinson AB, Kennedy A, Wiggam MI, Long-term remission rates after pituitary surgery for Cushing's disease: the need for long-term surveillance. Clin Endocrinol (Oxf) 2005;63:549-59
   PubMed Web of Science ®Google Scholar
• Patil CG, Veeravagu A, Prevedello DM, Outcomes after repeat transsphenoidal surgery for recurrent cushing's disease. Neurosurgery 2008;63:266-70
   PubMed Web of Science ®Google Scholar
• Aghi MK. Management of recurrent and refractory Cushing disease. Nat Clin Pract Endocrinol Metab 2008;4(10):560-8
   PubMedGoogle Scholar
• Mullan KR, Atkinson B. Endocrine clinical update: Where are we in the therapeutic management of pituitary-dependent hypercortisolism? Clin Endocrinol 2008;68:327-37
   PubMed Web of Science ®Google Scholar
• Castinetti F, Nagai M, Dufour H, Gamma knife radiosurgery is a successful adjunctive treatment in Cushing's disease. Eur J Endocrinol 2007;156:91-8
   PubMed Web of Science ®Google Scholar
• Jagannathan J, Sheehan JP, Pouratian N, Gamma Knife surgery for Cushing's disease. J Neurosurg 2007;106:980-7
   PubMed Web of Science ®Google Scholar
• Petit JH, Biller BM, Yock TI, Proton stereotactic radiotherapy for persistent adrenocorticotropin-producing adenomas. J Clin Endocrinol Metab 2008;93:393-9
   PubMed Web of Science ®Google Scholar
• Chow JT, Thompson GB, Grant CS, Bilateral laparoscopic adrenalectomy for corticotrophin-dependent Cushing's syndrome: a review of the Mayo Clinic experience. Clin Endocrinol (Oxf) 2008;68:513-19
   PubMed Web of Science ®Google Scholar
• Thompson SK, Hayman AV, Ludlam WH, Improved quality of life after bilateral laparoscopic adrenalectomy for Cushing's disease: a 10-year experience. Ann Surg 2007;245:790-94
   PubMed Web of Science ®Google Scholar
• Assie G, Bahurel H, Coste J, Corticotroph tumor progression after adrenalectomy in Cushing's disease: a reappraisal of Nelson's syndrome. J Clin Endocrinol Metab 2007;92:172-79
   PubMed Web of Science ®Google Scholar
• Miller JW, Crapo L. The medical treatment of Cushing's syndrome. Endocr Rev 1993;14(4):443-58
   PubMed Web of Science ®Google Scholar
• Nieman LK. Medical therapy of Cushing's disease. Pituitary 2002;5(2):77-82
   PubMedGoogle Scholar
• Arnaldi G, Cardinaletti M, Boscaro M. Advances in medical treatment of Cushing's disease. Expert Rev Endocrinol Metab 2007;2(6):735-43
   Google Scholar
• Alexandraki KI, Grossman AB. Pituitary-targeted medical therapy of Cushing's disease. Expert Opin Investig Drugs 2008;17(5):669-77
   PubMed Web of Science ®Google Scholar
• Castinetti F, Fassnacht M, Johanssen S, Merits and pitfalls of mifepristone in Cushing's syndrome. Eur J Endocrinol 2009;160(6):1003-10
   PubMed Web of Science ®Google Scholar
• Castinetti F, Morange I, Jaquet P, Ketoconazole revisited: a preoperative or postoperative treatment in Cushing's disease. Eur J Endocrinol 2008;158(1):91-9
   PubMed Web of Science ®Google Scholar
• Heaney AP, Fernando M, Yong WH, Melmed S. Functional PPAR-gamma receptor is a novel therapeutic target for ACTH-secreting pituitary adenomas. Nat Med 2002;8(11):1281-7
   PubMed Web of Science ®Google Scholar
• Ambrosi B, Dall'Asta C, Cannavo S, Effects of chronic administration of PPAR-gamma ligand rosiglitazone in Cushing's disease. Eur J Endocrinol 2004;151(2):173-8
   PubMed Web of Science ®Google Scholar
• Pivonello R, Ferone D, de Herder WW. Dopamine receptor expression and function in corticotroph pituitary tumors. J Clin Endocrinol Metab 2004;89(5):2452-62
   PubMed Web of Science ®Google Scholar
• Pivonello R, De Martino MC, Cappabianca P, The medical treatment of Cushing's disease: effectiveness of chronic treatment with the dopamine agonist cabergoline in patients unsuccessfully treated by surgery. J Clin Endocrinol Metab 2008;94(1):223-30
   PubMed Web of Science ®Google Scholar
• Bruns C, Lewis I, Briner U, SOM230: a novel somatostatin peptidomimetic with broad somatotropin release inhibiting factor (SRIF) receptor binding and a unique antisecretory profile. Eur J Endocrinol 2002;146(5):707-16
   PubMed Web of Science ®Google Scholar
• Hofland LJ, van der Hoek J, Feelders R, The multi-ligand somatostatin analogue SOM230 inhibits ACTH secretion by cultured human corticotroph adenomas via somatostatin receptor type 5. Eur J Endocrinol 2005;152(4):645–54
   PubMed Web of Science ®Google Scholar
• Patel YC. Somatostatin and its receptor family. Front Neuroendocrinol 1999;20(3):157-98
   PubMed Web of Science ®Google Scholar
• Kraus J, Woltje M, Schonwetter N, Hollt V. Alternative pro-moter usage and tissue specific expression of the mouse somatostatin receptor 2 gene. FEBS Lett 1998;3:165-170
   Google Scholar
• Weckbecker G, Lewis I, Albert R, Opportunities in somatostatin research: biological, chemical and therapeutic aspects [review]. Nat Rev Drug Discov 2003;2(12):999-1017. Erratum in: Nat Rev Drug Discov 2005;4(12):975
   PubMed Web of Science ®Google Scholar
• Ben-Shlomo A, Zhou C, Pichurin O, Constitutive somatostatin receptor activity determines tonic pituitary cell response. Mol Endocrinol 2009;23(3):337-48
   PubMed Web of Science ®Google Scholar
• Ferone D, Gatto F, Arvigo M, The clinical-molecular interface of somatostatin, dopamine and their receptors in pituitary pathophysiology. J Mol Endocrinol 2009;42(5):361-70
   PubMed Web of Science ®Google Scholar
• Liu Q, Bee MS, Schonbrunn A. Site specificity of agonist and second messenger-activated kinases for somatostatin receptor subtype 2A (Sst2A) phosphorylation. Mol Pharmacol 2009;76(1):68-80
   PubMed Web of Science ®Google Scholar
• Schonbrunn A. Selective agonism in somatostatin receptor signaling and regulation. Mol Cell Endocrinol 2008;286(1-2):35-9
   PubMed Web of Science ®Google Scholar
• Jacobs S, Schulz S. Intracellular trafficking of somatostatin receptors. Mol Cell Endocrinol 2008;286(1-2):58-62
   PubMed Web of Science ®Google Scholar
• Hofland LJ, Lamberts SW. The pathophysiological consequences of somatostatin receptor internalization and resistance. Endocr Rev 2003;24(1):28-47
   PubMed Web of Science ®Google Scholar
• Duran-Prado M, Malagon MM, Gracia-Navarro F, Castano JP. Dimerization of G protein-coupled receptors: new avenues for somatostatin receptor signalling,control and functioning. Mol Cell Endocrinol 2008;286(1-2):63-8
   PubMed Web of Science ®Google Scholar
• Grant M, Alturaihi H, Jaquet P, Cell growth inhibition and functioning of human somatostatin receptor type 2 are modulated by receptor heterodimerization. Mol Endocrinol 2008;22:2278-92
   PubMed Web of Science ®Google Scholar
• Ren SG, Kim S, Taylor J, Functional association of somatostatin receptor subtypes 2 and 5 in inhibiting human growth hormone secretion. J Clin Endocrinol Metab 2003;88:4239-45
   PubMed Web of Science ®Google Scholar
• Murray RD, Melmed S. A critical analysis of clinically available somatostatin analog formulations for therapy of acromegaly. J Clin Endocrinol Metab 2008;93(8):2957-68
   PubMed Web of Science ®Google Scholar
• Modlin IM, Pavel M, Kidd M, Gustafsson BI. Review article: somatostatin analogues in the treatment of gastroenteropancreatic neuroendocrine (carcinoid) tumours. Aliment Pharmacol Ther 2010;31(2):169-88
   PubMed Web of Science ®Google Scholar
• Van der Hoek J, Lamberts SW, Hofland LJ. The role of somatostatin analogs in Cushing's disease. Pituitary 2004;7(4):257-64
   PubMedGoogle Scholar
• Arnaldi G, Polenta B, Cardinaletti M, Boscaro M. Potential indications for somatostatin analogs in Cushing's syndrome. J Endocrinol Invest 2005;28(Suppl 11):106-10
   PubMedGoogle Scholar
• Lamberts SW, Uitterlinden P, Klijn JM. The effect of the long-acting somatostatin analogue SMS 201-995 on ACTH secretion in Nelson's syndrome and Cushing's disease. Acta Endocrinol (Copenh) 1989;6:760-66
   Google Scholar
• Stalla GK, Brockmeier SJ, Renner U, Octreotide exerts different effects in vivo and in vitro in Cushing's disease. Eur J Endocrinol 1994;2:125-31
   Google Scholar
• Ambrosi B, Bochicchio D, Fadin C, Failure of somatostatin and octreotide to acutely affect the hypothalamic-pituitary-adrenal function in patients with corticotropin hypersecretion. J Endocrinol Invest 1990;3:257-61
   Google Scholar
• Invitti C, de Martin M, Brunani A, Treatment of Cushing's syndrome with the long-acting somatostatin analogue SM 201-995 (sandostatin). Clin Endocrinol (Oxf) 1990;32(3):275-81
   PubMed Web of Science ®Google Scholar
• Batista DL, Zhang X, Gejman R, The effects of SOM230 on cell proliferation and adrenocorticotropin secretion in human corticotroph pituitary adenomas. J Clin Endocrinol Metab 2006;91(11):4482-8
   PubMed Web of Science ®Google Scholar
• Schonbrunn A. Glucocorticoids down-regulate somatostatin receptors on pituitary cells in culture. Endocrinology 1982;4:1147-54
   Google Scholar
• Kraus J, Woltje M, Hollt V. Regulation of mouse somatostatin receptor type 2 gene expression by glucocorticoids. FEBS Lett 1999;2:200-4
   Google Scholar
• Van der Hoek J, Waaijers M, van Koetsveld PM, Distinct functional properties of native somatostatin receptor subtype 5 compared with subtype 2 in the regulation of ACTH release by corticotroph tumor cells. Am J Physiol Endocrinol Metab 2005;289(2):E278-87
   PubMed Web of Science ®Google Scholar
• Strowski MZ, Dashkevicz MP, Parmar RM, Somatostatin receptor subtypes 2 and 5 inhibit corticotropin-releasing hormone-stimulated adrenocorticotropin secretion from AtT-20 cells. Neuroendocrinology 2002;6:339-46
   Google Scholar
• Cervia D, Nunn C, Fehlmann D, Pharmacological characterisation of native somatostatin receptors in AtT-20 mouse tumour corticotrophs. Br J Pharmacol 2003;1:109-21
   Google Scholar
• Stafford PJ, Kopelman PG, Davidson K, The pituitary-adrenal response to CRF-41 is unaltered by intravenous somatostatin in normal subjects. Clin Endocrinol (Oxf) 1989;30(6):661-6
   PubMed Web of Science ®Google Scholar
• Fehm HL, Voigt KH, Lang R, Somatostatin: a potent inhibitor of ACTH-hypersecretion in adrenal insufficiency. Klin Wochenschr 1976;4:173-5
   Google Scholar
• Ben-Shlomo A, Wawrowsky KA, Proekt I, Somatostatin receptor type 5 modulates somatostatin receptor type 2 regulation of adrenocorticotropin secretion. J Biol Chem 2005;280:24011-21
   PubMed Web of Science ®Google Scholar
• Ben-Shlomo A, Schmid H, Wawrowsky K, Differential ligand-mediated pituitary somatostatin receptor subtype signaling: implications for corticotroph tumor therapy. J Clin Endocrinol Metab 2009;94(11):4342-50
   PubMed Web of Science ®Google Scholar
• de Bruin C, Feelders RA, Lamberts SW, Hofland LJ. Somatostatin and dopamine receptors as targets for medical treatment of Cushing's Syndrome. Rev Endocr Metab Disord 2009;10(2):91-102
   PubMed Web of Science ®Google Scholar
• Hofland LJ. Somatostatin and somatostatin receptors in Cushing's disease. Mol Cell Endocrinol 2008;286(1-2):199-205
   PubMed Web of Science ®Google Scholar
• Schmid HA. Pasireotide (SOM230): development, mechanism of action and potential applications. Mol Cell Endocrinol 2008;286(1-2):69-74
   PubMed Web of Science ®Google Scholar
• Lesche S, Lehmann D, Nagel F, Differential effects of octreotide and pasireotide on somatostatin receptor internalization and trafficking in vitro. J Clin Endocrinol Metab 2009;94(2):654-61
   PubMed Web of Science ®Google Scholar
• Poll F, Lehmann D, Illing S, Pasireotide and octreotide stimulate distinct patterns of sst2A somatostatin receptor phosphorylation. Mol Endocrinol 2010;24(2):436-46
   PubMed Web of Science ®Google Scholar
• Cescato R, Loesch KA, Waser B, Agonist-biased signaling at the sst2A receptor: the multi-somatostatin analogs KE108 and SOM230 activate and antagonize distinct signaling pathways. Mol Endocrinol 2010;24(1):240-9
   PubMed Web of Science ®Google Scholar
• Schmid HA, Silva AP. Short- and long-term effects of octreotide and SOM230 on GH, IGF-I, ACTH, corticosterone and ghrelin in rats. J Endocrinol Invest 2005;28(Suppl 11):28-35
   PubMedGoogle Scholar
• Weckbecker G, Briner U, Lewis I, Bruns C. SOM230: a new somatostatin peptidomimetic with potent inhibitory effects on the growth hormone/insulin-like growth factor-I axis in rats, primates, and dogs. Endocrinology 2002;143(10):4123-30
   PubMed Web of Science ®Google Scholar
• Schmid HA, Brueggen J, Guitard P. Effect of a long acting release formulation of pasireotide (SOM230) on hormone secretion in rats. 89th Endocrine Society Annual Meeting ENDO2007, June 2–5, 2007, Toronto, Canada, Abstract Book, P3.337
   Google Scholar
• van der Hoek J, de Herder WW, Feelders RA, A single-dose comparison of the acute effects between the new somatostatin analog SOM230 and octreotide in acromegalic patients. J Clin Endocrinol Metab 2004;89:638-45
   PubMed Web of Science ®Google Scholar
• Ma P, Wang Y, van der Hoek J, Pharmacokinetic-pharmacodynamic comparison of a novel multiligand somatostatin analog, SOM230, with octreotide in patients with acromegaly. Clin Pharmacol Ther 2005;78(1):69-80
   PubMed Web of Science ®Google Scholar
• Farral A, Glusman JE, Buchelt A, Pasireotide (SOM230) effectively reduces pituitary tumor volume in patients with active acromegaly: results from a Phase II trial. 89th Endocrine Society Annual Meeting ENDO2007, June 2–5, 2007, Toronto, Canada, Abstract Book OR 53-4
   Google Scholar
• Kvlos L, Wiedenmann B, Oberg K, The SOM230 Carcinoid Study Group 2006. Safety and efficacy of pasireotide (SOM230) in patients with metastatic carcinoid tumors refractory or resistant to octreotide LAR: results from a Phase II trial. J Clin Oncol 2006 ASCO Annual Meeting Proceedings Post-Meeting Edition 2006;24(18S Suppl):4082
   Google Scholar
• Fedele M, De Martino I, Pivonello R, SOM230, a new somatostatin analogue, is highly effective in the therapy of growth hormone/prolactin-secreting pituitary adenomas. Clin Cancer Res 2007;13(9):2738-44
   PubMed Web of Science ®Google Scholar
• Hofland LJ, van der Hoek J, van Koetsveld PM, The novel somatostatin analog SOM230 is a potent inhibitor of hormone release by growth hormone- and prolactin-secreting pituitary adenomas in vitro. J Clin Endocrinol Metab 2004;89(4):1577-85
   PubMed Web of Science ®Google Scholar
• Zatelli MC, Piccin D, Vignali C, Pasireotide, a multiple somatostatin receptor subtypes ligand, reduces cell viability in non-functioning pituitary adenomas by inhibiting vascular endothelial growth factor secretion. Endocr Relat Cancer 2007;14(1):91-102
   PubMed Web of Science ®Google Scholar
• Danila DC, Haidar JN, Zhang X, Somatostatin receptor-specific analogs: effects on cell proliferation and growth hormone secretion in human somatotroph tumors. J Clin Endocrinol Metab 2001;86:2976-81
   PubMed Web of Science ®Google Scholar
• Nolan LA, Schmid HA, Levy A. Octreotide and the novel multireceptor ligand somatostatin receptor agonist pasireotide (SOM230) block the adrenalectomy-induced increase in mitotic activity in male rat anterior pituitary. Endocrinology 2007;148(6):2821-7
   PubMed Web of Science ®Google Scholar
• Cukier K, Tewari R, Kurth F, Significant response to pasireotide (SOM230) in the treatment of a patient with persistent, refractory Cushing's disease. Clin Endocrinol (Oxf) 2009;71(2):305-7
   PubMed Web of Science ®Google Scholar
• Dutreix C, Degen L, Schroller S, The safety, tolerability,and pharmacokinetics of multiple daily doses of SOM230, a novel multiligand somatostatin analog [abstract]. Proceedings of the 12th International Congress of Endocrinology, 31 August – 4 September, 2004. Lisbon, Portugal. Abstract p 761-5
   Google Scholar
• Boscaro M, Ludlam WH, Atkinson B, Treatment of pituitary-dependent Cushing's Disease with Multireceptor Ligand Somatostatin Analog Pasireotide (SOM230): a multicenter, Phase II Trial. J Clin Endocrinol Metab 2009;94(1): 115-22
   PubMed Web of Science ®Google Scholar
• Boscaro M, Zhang Y, Sen K, on behalf of the Pasireotide Cushing's Disease Study Group UFC response is related to pasireotide (SOM230) plasma concentrations in patients with Cushing's disease [abstract]. 26 – 30 March 2010 14th International Congress of Endocrinology (ICE), Kyoto, Japan; 2010. p. 7-6-4
   Google Scholar
• Unger N, Serdiuk I, Sheu SY, Immunohistochemical localization of somatostatin receptor subtypes in benign and malignant adrenal tumours. Clin Endocrinol (Oxf) 2008;68:850-57
   PubMed Web of Science ®Google Scholar
• de Bruin C, Pereira AM, Feelders RA, Co-expression of dopamine and somatostatin receptor subtypes in corticotroph adenomas. J Clin Endocrinol Metab 2009;94(4):1118-24
   Google Scholar
• de Bruin C, Feelders RA, Waaijers AM, Differential regulation of human dopamine D2 and somatostatin receptor subtype expression by glucocorticoids in vitro. J Mol Endocrinol 2009;42(1):47-56
   PubMed Web of Science ®Google Scholar
• Dalm VA, Hofland LJ, Lamberts SW. Future clinical prospects in somatostatin/cortistatin/somatostatin receptor field. Mol Cell Endocrinol 2008;286(1-2):262-77
   PubMed Web of Science ®Google Scholar
• Feelders RA, de Bruin C, Pereira AM, Pasireotide alone or with cabergoline and ketoconazole in Cushing's disease. N Engl J Med 2010;362(19):1846-8
   PubMed Web of Science ®Google Scholar